Stock SEER SEER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Seer, Inc.

Equities

SEER

US81578P1066

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.8 USD +1.69% Intraday chart for Seer, Inc. -9.09% -7.22%
May. 08 Earnings Flash (SEER) SEER Posts Q1 Revenue $3.1M, vs. Street Est of $3.8M MT
May. 08 Transcript : Seer, Inc., Q1 2024 Earnings Call, May 08, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (SEER) SEER Posts Q1 Revenue $3.1M, vs. Street Est of $3.8M
Transcript : Seer, Inc., Q1 2024 Earnings Call, May 08, 2024
Seer, Inc. announces an Equity Buyback for $25 million worth of its shares.
Seer Reports First Quarter 2024 Financial Results
Seer, Inc. Provides Revenue Guidance for the Full Year 2024
Seer, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
Seer, Inc. Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
Seer, Inc. authorizes a Buyback Plan.
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
Transcript : Seer, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Seer, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Seer, Inc. Provides Revenue Guidance for the Full Year 2024
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Earnings Flash (SEER) SEER Reports Q4 Revenue $4.4M, vs. Street Est of $4.05M
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SEER Stock
  4. News Seer, Inc.
  5. Other languages